CS
JSPR icon

Credit Suisse’s Jasper Therapeutics JSPR Stock Holding History

Credit Suisse’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,750
Closed -$273K – 4389
2020
Q3 		$273K Hold
2,750
– – ﹤0.01% 3699
2020
Q2 		$275K Sell
2,750
-2,500
-48% -$244K ﹤0.01% 3621
2020
Q1 		$501K Buy
+5,250
New +$514K ﹤0.01% 3112

Other funds holding JSPR

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return
SRCM
Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
PMAM
Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Credit Suisse's JSPR Position: Q4 2020 in Review

Credit Suisse sold out of Jasper Therapeutics (JSPR) in Q4 2020, closing a stake of 2,750 shares — an estimated $273K sold.

Credit Suisse first reported a position in JSPR in Q1 2020 and held it in 3 quarters. The position peaked at $501K in Q1 2020. 51 funds tracked by Wall St. Rank hold JSPR as of Q4 2020.

  • Credit Suisse reported no remaining Jasper Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Credit Suisse sold 2,750 Jasper Therapeutics shares in Q4 2020, an estimated $273K.
  • Credit Suisse first reported a position in Jasper Therapeutics in Q1 2020 and held it in 3 quarters.
  • Credit Suisse's Jasper Therapeutics position peaked at $501K in Q1 2020.
  • 51 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q4 2020.

Based on Credit Suisse's 13F filing for Q4 2020, filed 12 Feb 2021.